arrow
E

Elliot Stieglitz

university of california
H指数:23
被引数:2,278

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

COAGULATIVE ABNORMALITIES IN PATIENTS WITH CBL SYNDROME
2025-11-010
OAAI
Multi-selective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML

多选择性RAS(ON)抑制剂靶向癌基因RAS,并克服RAS介导的FLT3i和BCL2i在AML中的耐药性

Blood
IF23.1
2025-10-290
PRE
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells

靶向高风险多发性骨髓瘤基因型,采用优化的抗CD70 CAR T细胞

Blood
IF23.1
2025-05-150
OA
Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia

靶向CLL-1的细胞免疫疗法治疗幼年型髓单核细胞白血病

2025-04-230
OA
CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition

CDK8 抑制在急性髓系白血病细胞中抑制单核细胞样基因表达,并拮抗体内对 FLT3 抑制的抵抗

BLOOD
IF23.1
2024-11-050
PRE
Integrative longitudinal genomic analysis of therapy-resistant and metastatic pediatric cancers
2024-03-220
PRE
LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia
2023-12-280
OAAI
Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target
2023-10-304
OAAI
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
2022-12-019
OAAI
Classification of rare pediatric myeloid neoplasia-Quo vadis?

罕见的小儿髓系肿瘤的分类-Quo vadis?

LEUKEMIA
IF13.4
2022-10-216
PRE